within Pharmacolibrary.Drugs.ATC.N;

model N06AX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.26666666666666666,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Minaprine is a reversible inhibitor of monoamine oxidase A (MAO-A) and has additional serotonergic and dopaminergic activity. It was marketed as an antidepressant drug in France but has since been withdrawn due to concerns regarding its safety profile, particularly risk of convulsions. It is not approved or used clinically today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical healthy adult after oral administration as no comprehensive PK human studies with full compartmental model parameters published.</p><h4>References</h4><ol><li>J P Kan, C Mouget-Goniot, P Worms, K Biziere,Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat.,Biochemical pharmacology,1986<a href='https://pubmed.ncbi.nlm.nih.gov/3954800/'>https://pubmed.ncbi.nlm.nih.gov/3954800/</a></li><li>H Davi, J M Bonnet, Y Berger,Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators.,Xenobiotica; the fate of foreign compounds in biological systems,1992<a href='https://pubmed.ncbi.nlm.nih.gov/1632106/'>https://pubmed.ncbi.nlm.nih.gov/1632106/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AX07;
